Evonik launches European API manufacturing capacity expansion programme

EUR 25 million first stage expected to be completed by mid-2021 as COVID-19 pandemic highlights need for more European capacity

The EUR 25 million first stage of the expansion project is scheduled to be completed by the middle of 2021, with the entire project expected to be finalized by 2024.

“The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets,” said Thomas Riermeier, senior vice president of Evonik’s Health Care business line. “The expansion of our Dossenheim and Hanau sites in Germany is now underway to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.”

Dr. Andreas Meudt, vice president of exclusive synthesis for the Health Care business line of Evonik said the expansion of the two multi-purpose cGMP sites would widen the company’s ability to support highly complex customer projects, such as those for oncological, anti-viral and other specialized drug products, which typically require continuous processing, highly pure PEGs and mPEGs, catalysis and cryogenic chemistry.